ICV administration of low doses of STZ, by changing insulin receptor tyrosine kinase activity and disrupting insulin receptor signaling, causes insulin resistance in the brain, followed by a decrease in glucose and energy metabolism [17]. This evidence concerns the gene INSR and Insulin resistance.